New Insights into the Efficacy of Naltrexone Based on Trajectory-Based Reanalyses of Two Negative Clinical TrialsBiological Psychiatry
Article in Press, Corrected Proof Available on-line 16 January 2007
Ralitza Gueorguievaa, c, E-mail: ralitza.gueorguieva@yale.edu
Ran Wub,
Brian Pittmanb,
Joyce Cramerb,
Stephanie S. O'Malleyb and
John H. Krystalb, c
aDepartments of Epidemiology and Public Health
bPsychiatryYale University School of Medicine, New Haven
cVeterans Affairs Connecticut Healthcare SystemWest Haven, Connecticut
Received 21 July 2006; revised 19 September 2006; accepted 19 September 2006. Available online 16 January 2007.
Background
The heterogeneity of clinical findings in studies evaluating the efficacy of naltrexone in the treatment of alcohol dependence has led to growing efforts to explore novel approaches to data analysis. The objective of this study was to identify distinct trajectories of daily drinking over time in two negative clinical trials and to determine whether naltrexone affected the probability to follow a particular trajectory.
Methods
The Veterans Affairs (VA) Cooperative Study #425 and the Women's Naltrexone Study failed to demonstrate efficacy on primary outcome variables. Separately for each study, we analyzed daily indicators of any drinking and heavy drinking using a semiparametric group-based approach.
Results
We estimated three distinct trajectories of daily drinking (both any and heavy drinking) which we described as “abstainer,” “sporadic drinker,” and “consistent drinker.” Naltrexone doubled the odds of following the abstainer trajectory instead of the consistent drinker trajectory but did not significantly change the odds of following the abstainer trajectory as contrasted with the sporadic drinker trajectory.
Conclusions
Naltrexone may have a clinically meaningful effect for alcohol-dependent patients with a high chance of consistent drinking, even in studies where it failed to show efficacy in planned analyses.
